US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

BlossomHill Therapeutics, Inc. - Common Stock (NQ:BLSM)

13.94 -1.04 (-6.94%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about BlossomHill Therapeutics, Inc. - Common Stock

News headline image
BlossomHill Therapeutics Presents Preclinical Data on Novel Pan-KRAS Inhibitor, BH-501284, at the AACR Conference on Pancreatic Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Reports Second Quarter 2026 Financial Results
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics to Present at the 8th Annual RAS-Targeted Drug Development Summit & H.C. Wainwright 28th Annual Global Investment Conference
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics to Present Updated Data from Ongoing Phase 1/2 SOLARA Trial of its Macrocyclic OMNI-EGFR™ Inhibitor, BH-30643, in EGFR-mutant NSCLC at the 2026 World Conference on Lung Cancer
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire
News headline image
BlossomHill Therapeutics Announces FDA Fast Track Designation for BH-30643, a Macrocyclic OMNI-EGFR™ Inhibitor for the Treatment of Advanced EGFR C797S-positive NSCLC
From BlossomHill Therapeutics, Inc.
Via GlobeNewswire